REGN Latest Press Releases

-- February 24, 2026 --

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Globe Newswire 9:30 AM

Dupixent (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) Globe Newswire 9:30 AM

-- February 19, 2026 --

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Globe Newswire 7:00 AM

-- February 17, 2026 --

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight PRNewswire 5:31 PM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 11, 2026 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- February 10, 2026 --

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy Globe Newswire 7:00 AM

-- February 2, 2026 --

EYLEA HD (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases Globe Newswire 7:00 AM

-- January 30, 2026 --

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Globe Newswire 6:30 AM

-- January 21, 2026 --

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search Globe Newswire 12:00 PM

-- January 2, 2026 --

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 Globe Newswire 4:05 PM

-- December 7, 2025 --

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment Globe Newswire 4:30 PM

-- December 1, 2025 --

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) Globe Newswire 7:00 AM

-- November 25, 2025 --

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Globe Newswire 1:00 AM

Dupixent (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) Globe Newswire 1:00 AM

-- November 19, 2025 --

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications Globe Newswire 4:10 PM

Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation Globe Newswire 7:00 AM

-- November 13, 2025 --

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs Globe Newswire 7:00 AM

-- November 8, 2025 --

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet Globe Newswire 10:46 AM

-- November 7, 2025 --

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Globe Newswire 8:00 AM

Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review Globe Newswire 8:00 AM

-- November 3, 2025 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- October 31, 2025 --

Dupixent (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award Globe Newswire 7:00 AM

-- October 29, 2025 --

OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Globe Newswire 8:00 AM

-- October 28, 2025 --

Regeneron Reports Third Quarter 2025 Financial and Operating Results Globe Newswire 6:30 AM

-- October 17, 2025 --

Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation Globe Newswire 7:30 AM

-- October 15, 2025 --

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers Globe Newswire 7:00 AM

-- October 12, 2025 --

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss Globe Newswire 10:18 AM

-- October 8, 2025 --

Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation Globe Newswire 2:31 PM

-- September 30, 2025 --

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 Globe Newswire 4:05 PM

-- September 26, 2025 --

Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol Globe Newswire 7:00 AM